Kymera Therapeutic/$KYMR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kymera Therapeutic
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
- Ticker
- $KYMR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 285
- Headquarters
- Watertown, United States
- Website
- www.kymeratx.com
KYMR Metrics
BasicAdvanced
$11B
-
-$3.62
2.03
-
Price and volume
Market cap
$11B
Beta
2.03
52-week high
$138.00
52-week low
$56.75
Average daily volume
950K
Financial strength
Current ratio
11.13
Quick ratio
10.825
Long term debt to equity
0.039
Total debt to equity
0.047
Interest coverage (TTM)
-1,340.70%
Profitability
EBITDA (TTM)
-398.383
Gross margin (TTM)
-320.58%
Net profit margin (TTM)
-341.79%
Operating margin (TTM)
-396.04%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-17.64%
Return on equity (TTM)
-27.29%
Valuation
Price to revenue (TTM)
124.289
Price to book
6.96
Price to tangible book (TTM)
6.96
Price to free cash flow (TTM)
-43.984
Free cash flow yield (TTM)
-2.27%
Free cash flow per share (TTM)
-2.995
Growth
Revenue change (TTM)
133.76%
Earnings per share change (TTM)
0.70%
3-year revenue growth (CAGR)
29.71%
3-year earnings per share growth (CAGR)
7.99%
What the Analysts think about KYMR
Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.
Analyst projections of the future price of Kymera Therapeutic stock.
Bulls say / Bears say
Kymera completed the 16-week KT-621 Phase 2b atopic dermatitis study and expects results by year-end 2026, bringing a major clinical catalyst close. Positive data could support its plan to begin Phase 3 in 2027. (Kymera Therapeutics)
KT-579 showed at least 90% median IRF5 degradation at several doses, strong suppression of immune biomarkers and a safety profile comparable to placebo in its Phase 1 healthy-volunteer trial. This provides encouraging early evidence for a new oral approach to autoimmune disease. (Kymera Therapeutics)
Partnered programmes add potential beyond Kymera’s own trials: Sanofi has started Phase 1 testing of IRAK4 degrader KT-485, triggering a $20 million milestone, while Gilead is advancing a separate candidate towards an expected 2027 filing. (Kymera Therapeutics)
KT-621’s Phase 2b efficacy data are still pending, and management’s Phase 3 timetable depends on supportive results and regulator discussions. Until the readout, its early clinical promise has not established that it works well enough in a larger trial. (Kymera Therapeutics, U.S. Securities and Exchange Commission)
KT-579’s positive results so far come from healthy volunteers, not people with lupus. Its planned trial is only about 30 patients and is designed mainly to test biomarkers, so meaningful clinical benefit remains unproven. (Kymera Therapeutics)
Kymera remains loss-making and has no approved products; its third-quarter net loss widened to $132 million from $82 million a year earlier. A large cash balance provides time, but ongoing development spending leaves the business reliant on future pipeline progress to support its costs. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
KYMR Financial Performance
Revenues and expenses
KYMR Earnings Performance
Company profitability
Upcoming events
No upcoming events
KYMR News
AllArticlesVideos
Funds containing KYMR
AllUSDEURGBP
Fund name | Fund size | $KYMR weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 0.80% |
ARK Genomic Revolution£ARCG | $123M | 0.80% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.70% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.70% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.28% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.